Beerse, Belgium (ots/PRNewswire) - - Janssen presents one-year data from continued Phase 2 lupus study during plenary session at 2018 American College of Rheumatology (ACR) / Association for Rheumatology Health Professionals (ARHP) Annual Meeting The Janssen Pharmaceutical Companies of Johnson & Johnson today ...
Beerse, Belgium (ots/PRNewswire) - - One-year results from the Phase 2 study evaluating STELARA® (ustekinumab) in patients with active systemic lupus erythematosus featured in a plenary presentation - 13 presentations from approved and pipeline products provide real-world treatment and disease insights across ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE ONLY The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that ten company-sponsored abstracts will be presented at the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam, Netherlands being held on 13-16 June. Data from the ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY - 60% of patients receiving ustekinumab showed significant reductions in lupus disease activity vs. 31% of patients receiving placebo - Ustekinumab showed significant improvements in various disease measures compared with placebo, including ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY Longer-term results demonstrate continued efficacy of anti-interleukin 23 monoclonal antibody guselkumab in improving joint and skin symptoms associated with active psoriatic arthritis Janssen Research & Development, LLC (Janssen) announced today ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY Longer-term results demonstrate continued efficacy of anti-interleukin 23 monoclonal antibody guselkumab in improving joint and skin symptoms associated with active psoriatic arthritis Janssen Research & Development, LLC (Janssen) announced today ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY - 60% of patients receiving ustekinumab showed significant reductions in lupus disease activity vs. 31% of patients receiving placebo - Ustekinumab showed significant improvements in various disease measures compared with placebo, including ...
Beerse, Belgium (ots/PRNewswire) - Janssen announces results of pan-European research which shows that a third of psychiatrists (34%) delay conversations about the full range of treatment options with their patients living with schizophrenia. The 'Open Minds' survey, conducted among 347 psychiatrists across eight ...
Beerse, Belgium (ots/PRNewswire) - FOR UK AND EMEA MEDICAL MEDIA ONLY Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a change to the terms of the marketing ...
Beerse, Belgium (ots/PRNewswire) - New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C worldwide 'Tackling hepatitis C: Moving towards an integrated policy approach', a report published by The Economist Intelligence Unit (EIU) today reveals that many ...
Beerse, Belgium (ots/PRNewswire) - /NOT INTENDED FOR UK MEDIA/ Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology Three year follow-up data from the Phase 1b/2 PCYC-1102 trial of monotherapy ibrutinib showed continued ...
Beerse, Belgium (ots/PRNewswire) - /NOT INTENDED FOR UK MEDIA/ Phase 3 data (Abstract LBA7008) featured in the official press programme of the 50th annual meeting of the American Society of Clinical Oncology and simultaneously published in The New England Journal of Medicine Data from the international, multicentre ...
Beerse, Belgium (ots/PRNewswire) - - Research in haematological malignancies features VELCADE(R), siltuximab, ibrutinib and daratumumab - Note: This release corresponds to EHA abstracts S1345, P958, P957, P369, P353, P960, P1211, P1209, P461, P356, P350, P434, P109 Janssen Pharmaceutica NV announced data related to ...
Beerse, Belgium (ots/PRNewswire) - -- Addressing chronic diseases key to sustainable healthcare reform in Europe Janssen Pharmaceutica NV (Janssen) has commissioned a new report based on independent research by The Swedish Institute of Health Economics[1] presented alongside the 2014 EU Summit on Chronic Diseases in Brussels today. The 'Access to high-quality oncology ...
Janssen-Cilag International NV (Janssen)
Beerse, Belgium (ots/PRNewswire) - Janssen-Cilag International NV (Janssen), today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for a once-daily single tablet fixed-dose antiretroviral combination product containing darunavir, a protease inhibitor ...
Janssen Infectious Diseases-Diagnostics BVBA
Beerse, Belgium (ots/PRNewswire) - -INCIVO(R) triple therapy now offers a twice daily HCV treatment regimen which should improve patient adherence[1] - Janssen Infectious Diseases-Diagnostics BVBA (Janssen) announced today that the European Commission (EC) has approved a new twice daily (BID) dosing of INCIVO(R) ...
Beerse, Belgium (ots/PRNewswire) - - OPTIMIZE study results presented at EASL show similar sustained virological response (SVR12) rates in patients with fibrosis or cirrhosis receiving an INCIVO(R)(telaprevir) combination treatment twice daily versus every eight hours - Janssen Infectious Diseases-Diagnostics BVBA ...
Beerse, Belgium (ots/PRNewswire) - NOT INTENDED FOR US JOURNALISTS - OPTIMIZE study results to be presented in late-breaking poster presentation at the American Association for the Study of Liver Diseases (AASLD) 2012 show non-inferior sustained virological response (SVR12) rates in previously untreated genotype-1 ...
Janssen-Cilag International NV (Janssen)
Beerse, Belgium (ots/PRNewswire) - Janssen-Cilag International NV (Janssen) today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) seeking conditional approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part ...
Janssen-Cilag International NV (Janssen)
Beerse, Belgium (ots/PRNewswire) - Janssen-Cilag International NV (Janssen) announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for the use of canagliflozin, an investigational, oral, once-daily sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 ...
Beerse, Belgium And Raritan, New Jersey (ots/PRNewswire) - ? Simultaneous Submissions Based on Data from Pre-chemo Prostate Cancer Study Janssen-Cilag International NV announced today it has submitted a type II variation to the European Medicines Agency (EMA) for ZYTIGA(R); simultaneously, Janssen Research & ...